Author:
Mendoza-Alvarez Alejandro,Tosco-Herrera Eva,Muñoz-Barrera Adrian,Rubio-Rodríguez Luis A.,Alonso-Gonzalez Aitana,Corrales Almudena,Iñigo-Campos Antonio,Almeida-Quintana Lourdes,Martin-Fernandez Elena,Martinez-Beltran Dara,Perez-Rodriguez Eva,Callero Ariel,Garcia-Robaina Jose C.,González-Montelongo Rafaela,Marcelino-Rodriguez Itahisa,Lorenzo-Salazar Jose M.,Flores Carlos
Abstract
Hereditary angioedema (HAE) is a rare disease where known causes involve C1 inhibitor dysfunction or dysregulation of the kinin cascade. The updated HAE management guidelines recommend performing genetic tests to reach a precise diagnosis. Unfortunately, genetic tests are still uncommon in the diagnosis routine. Here, we characterized for the first time the genetic causes of HAE in affected families from the Canary Islands (Spain). Whole-exome sequencing data was obtained from 41 affected patients and unaffected relatives from 29 unrelated families identified in the archipelago. The Hereditary Angioedema Database Annotation (HADA) tool was used for pathogenicity classification and causal variant prioritization among the genes known to cause HAE. Manual reclassification of prioritized variants was used in those families lacking known causal variants. We detected a total of eight different variants causing HAE in this patient series, affecting essentially SERPING1 and F12 genes, one of them being a novel SERPING1 variant (c.686-12A>G) with a predicted splicing effect which was reclassified as likely pathogenic in one family. Altogether, the diagnostic yield by assessing previously reported causal genes and considering variant reclassifications according to the American College of Medical Genetics guidelines reached 66.7% (95% Confidence Interval [CI]: 30.1-91.0) in families with more than one affected member and 10.0% (95% CI: 1.8-33.1) among cases without family information for the disease. Despite the genetic causes of many patients remain to be identified, our results reinforce the need of genetic tests as first-tier diagnostic tool in this disease, as recommended by the international WAO/EAACI guidelines for the management of HAE.
Funder
Ministerio de Ciencia e Innovación
Instituto de Salud Carlos III
Instituto Tecnológico y de Energías Renovables
Cabildo de Tenerife
Fundación de la Sociedad Española de Alergología e Inmunología Clínica
Agencia Canaria de Investigación, Innovación y Sociedad de la Información
Subject
Immunology,Immunology and Allergy
Reference81 articles.
1. Hereditary angioedema: a broad review for clinicians;Nzeako;Arch Intern Med,2001
2. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond;Agostoni;J Allergy Clin Immunol,2004
3. Pathways for bradykinin formation and inflammatory disease;Kaplan;J Allergy Clin Immunol,2002
4. An update on the genetics and pathogenesis of hereditary angioedema;Banday;Genes Dis,2019
5. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. part i. classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis;Caballero;J Investig Allergol Clin Immunol,2011
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献